Sinovac Biotech Ltd. Files 6-K Report
Ticker: SVA · Form: 6-K · Filed: Nov 20, 2025
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, regulatory-filing
TL;DR
Sinovac Biotech (SVA) filed a 6-K, standard foreign issuer update. Nothing major.
AI Summary
Sinovac Biotech Ltd. filed a Form 6-K on November 20, 2025, for the month of November 2025. The report is for a foreign private issuer and indicates the company files annual reports under Form 20-F. The filing was signed by Chiang Li on behalf of Sinovac Biotech Ltd., located at No. 39 Shangdi Xi Road, Haidian District, Beijing, People's Republic of China.
Why It Matters
This filing provides routine updates for investors regarding Sinovac Biotech Ltd.'s status as a foreign private issuer and its reporting obligations.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.
Key Players & Entities
- Sinovac Biotech Ltd. (company) — Filer of the report
- Chiang Li (person) — Signatory for the company
- Beijing (location) — Company headquarters location
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that provides information which the issuer makes or is required to make public pursuant to the laws of the issuer's home country or jurisdiction, or which it furnishes or makes public to its security holders.
What is the filing date of this report?
The filing date of this report is November 20, 2025.
Which form does Sinovac Biotech Ltd. use for its annual reports?
Sinovac Biotech Ltd. files its annual reports under cover of Form 20-F.
Where is Sinovac Biotech Ltd. headquartered?
Sinovac Biotech Ltd. is headquartered at No. 39 Shangdi Xi Road, Haidian District, Beijing, People's Republic of China.
Who signed this Form 6-K on behalf of Sinovac Biotech Ltd.?
The Form 6-K was signed by Chiang Li on behalf of Sinovac Biotech Ltd.
Filing Stats: 147 words · 1 min read · ~1 pages · Grade level 13.3 · Accepted 2026-01-30 15:23:55
Filing Documents
- ea0266375-6k_sinovac.htm (6-K) — 10KB
- ea026637501ex99-1_sinovac.htm (EX-99.1) — 12KB
- 0001213900-25-112846.txt ( ) — 22KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number: 001-32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Rd, Haidian District Beijing 100085, People’s Republic of China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SINOVAC BIOTECH LTD. By: /s/ Chiang Li Name: Chiang Li Title: Member of the Board Date: November 18, 2025 1 Exhibit Index Exhibit 99.1 Press Release 2